ZLSCF (ZYUS Life Sciences) Total Equity: $-17.46 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is ZYUS Life Sciences Total Equity?

ZYUS Life Sciences ZLSCF Total Equity is $-17.46 Mil as of Mar. 2026. The stock has 7 warning signs investors should review.

ZYUS Life Sciences's total equity for the quarter that ended in Mar. 2026 was $-17.46 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

ZYUS Life Sciences Total Equity Historical Data

* Premium members only.

The historical data trend for ZYUS Life Sciences's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ZYUS Life Sciences Total Equity Chart

ZYUS Life Sciences Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
0.00 3.49 17.23 -3.75 -15.31

ZYUS Life Sciences Quarterly Data
Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.20 -7.16 -9.37 -15.31 -17.46

ZYUS Life Sciences Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

ZYUS Life Sciences's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=3.68-18.989
=-15.31

ZYUS Life Sciences's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=3.405-20.862
=-17.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $-17.46 Mil mean?
ZYUS Life Sciences (ZLSCF) has a Total Equity of $-17.46 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for ZYUS Life Sciences and its competitors.
Is ZYUS Life Sciences' Total Equity too high?
ZYUS Life Sciences' current Total Equity is $-17.46 Mil.
How does ZYUS Life Sciences' Total Equity compare to RMTI and BTAI?
ZYUS Life Sciences' Total Equity of $-17.46 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for ZYUS Life Sciences and its competitors. ZYUS Life Sciences's current Total Equity is $-17.46 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ZYUS Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, ZYUS Life Sciences (ZLSCF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.60, compared to a current price of $0.01 — trading 97.7% below its estimated fair value. The current Total Equity is $-17.46 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For ZYUS Life Sciences (ZLSCF), the current Total Equity is $-17.46 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ZYUS Life Sciences Business Description

Other Exchanges ZYUS:Canada
Address 407 Downey Road, Unit 204, Saskatoon, SK, CAN, S7N 4L8
ZYUS Life Sciences Corp is primarily engaged in the world-wide development and commercialization of cannabinoid-based therapeutics and product candidates. It is a licensed producer and distributor of medical cannabis for both medical and adult recreational access in Canada. The company has one reportable segment: Bio-pharmaceutical Products (including medical cannabis derivatives). Geographically, it operates in Canada; United States; Australia; and European Union.